Abeona Therapeutics Enrolls First High-Dose Subject in Ongoing Phase I/II Trial

Abeona Therapeutics enrolls the first high-dose subject in the ongoing Phase I/II trial for ABO-102 utilizing a single intravenous injection of AAV gene therapy for patients with Sanfilippo syndrome type A.

Read More  >